AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London
ALAMEDA, Calif.--(BUSINESS WIRE)--May 17, 2018--
Therapeutics, Inc., a subsidiary of BioTime,
Inc. (NYSE American: BTX), today announced that the company’s Chief
Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of
BioTime, will deliver a keynote presentation at World
Advanced Therapies & Regenerative Medicine Congress, May 16-18
Taking place on Friday, May 18 at 12:30pm BST, Dr. West’s presentation,
“Aging and Regeneration: Commercial Implications of the New Science”
will address the following topics related to AgeX’s programs:
How can molecular and AI technologies help regenerate damaged tissue
What are the current challenges with induced tissue regeneration and
how are we tackling them?
Combining pluripotent stem cell and iTR technology to form new company
A copy of Dr. West’s presentation will be available on the AgeX website.
About AgeX Therapeutics
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American:
BTX), is a biotechnology company applying technology relating to
cellular immortality and regenerative biology to aging and age-related
diseases. The company has three initial areas of product development:
pluripotent stem cell-derived brown adipocytes (AGEX-BAT1); vascular
progenitors (AGEX-VASC1); and induced Tissue Regeneration (iTR). Initial
planned indications for these products are Type 2 diabetes, cardiac
ischemia, and tissue regeneration respectively. For more information,
please visit www.agexinc.com
or connect with the company on Twitter,
BioTime is a clinical-stage biotechnology company focused on
degenerative diseases. Its clinical programs are based on two platform
technologies: cell replacement and cell/drug delivery. With its cell
replacement platform, BioTime is creating new cells and tissues with its
proprietary pluripotent cell technologies. These cells and tissues are
developed to replace those that are either rendered dysfunctional or
lost due to degenerative diseases. BioTime’s cell/drug delivery programs
are based upon its proprietary HyStem® cell and drug delivery matrix
technology. HyStem® was designed to provide for the transfer, retention,
engraftment and metabolic support of cellular replacement therapies.
BioTime’s lead cell delivery clinical program is Renevia®, which
consists of HyStem® combined with the patient's own adipose (fat)
progenitor cells. Renevia® met its primary endpoint in an EU pivotal
clinical trial for the treatment of facial lipoatrophy in HIV patients
in 2017. BioTime has submitted Renevia® for CE Mark approval in the EU.
There were no device related serious adverse events reported to date.
BioTime’s lead cell replacement product candidate is OpRegen®, a retinal
pigment epithelium transplant therapy, which is in a Phase I/IIa
multicenter clinical trial for the treatment of dry age-related macular
degeneration, the leading cause of blindness in developing countries.
There were no related serious adverse events reported to date in the
first nine patients. BioTime also has significant equity holdings in two
publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE
American: AST) and OncoCyte Corporation (NYSE American: OCX), and a
private company, AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: BioTime
Certain statements contained in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements pertaining to product technology,
clinical development, regulatory approval timelines, the success of
potential cosmetic applications and potential opportunities for BioTime,
Inc. and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the business of BioTime, Inc. and its
subsidiaries, particularly those mentioned in the cautionary statements
found in more detail in the “Risk Factors” section of its Annual Reports
on Form 10-K and Quarterly Reports on Form 10-Q filed with
the SEC (copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. BioTime specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date of
this release, except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180517005414/en/
Source: AgeX Therapeutics, Inc.
Investor Contact for BioTime:
David Nakasone, 510-871-4188
Contact for AgeX:
Level Agency, Inc.
Mark Leonard, 847-651-9682